Try our Advanced Search for more refined results
Federal Trade Commission V. Amgen Inc., et al.
Case Number:
1:23-cv-03053
Court:
Nature of Suit:
Judge:
Firms
- Bryan Cave
- Cooley LLP
- Cotsirilos Tighe
- Covington & Burling
- Cravath Swaine
- MoloLamken
- Smith Gambrell
- Sullivan & Cromwell
- Weil Gotshal
Companies
- Amgen Inc.
- Horizon Therapeutics PLC
- Pharmaceutical Research & Manufacturers of America
- Regeneron Pharmaceuticals Inc.
Government Agencies
Sectors & Industries:
-
June 23, 2023
6 States Join FTC's Challenge To Amgen's $28B Horizon Buy
Illinois and California are among six states that have joined the Federal Trade Commission's antitrust suit against Amgen's planned $28 billion purchase of Horizon Therapeutics, the maker of the drug Tepezza for thyroid eye disease and Krystexxa for chronic refractory gout.
-
June 12, 2023
Amgen, Horizon Blast FTC's 'Speculation On Speculation'
Amgen and Horizon Therapeutics insisted that the Federal Trade Commission's challenge to their merger is undone by real-world market dynamics that make it impractical to bundle products that, as the agency alleges, will force customers to stick with a pair of drug monopolies.
-
May 18, 2023
Takeaways From FTC's Challenge Of Amgen Deal
The Federal Trade Commission's move this week to block Amgen Inc.'s proposed $27.8 billion purchase of Horizon Therapeutics PLC shows an aggressive attack by enforcers on a transaction that may not have gotten much scrutiny in the past.
-
May 16, 2023
FTC Challenges $28B Amgen-Horizon Therapeutics Merger
The Federal Trade Commission on Tuesday sought to shut down U.S. biotechnology company Amgen Inc.'s proposed $27.8 billion purchase of Ireland-based drugmaker Horizon Therapeutics PLC, filing a lawsuit in federal court to block the transaction.
- ← Previous
- 1
- 2
- Next →